Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease
Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng
Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng
View: Text | PDF
Research Article Nephrology Stem cells

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

  • Text
  • PDF
Abstract

Chronic kidney disease (CKD) induces the failure of arteriovenous fistulas (AVFs) and promotes the differentiation of vascular adventitial GLI1-positive mesenchymal stem cells (GMCs). However, the roles of GMCs in forming neointima in AVFs remain unknown. GMCs isolated from CKD mice showed increased potential capacity of differentiation into myofibroblast-like cells. Increased activation of expression of PDGFRA and hedgehog (HH) signaling were detected in adventitial cells of AVFs from patients with end-stage kidney disease and CKD mice. PDGFRA was translocated and accumulated in early endosome when sonic hedgehog was overexpressed. In endosome, PDGFRA-mediated activation of TGFB1/SMAD signaling promoted the differentiation of GMCs into myofibroblasts, extracellular matrix deposition, and vascular fibrosis. These responses resulted in neointima formation and AVF failure. KO of Pdgfra or inhibition of HH signaling in GMCs suppressed the differentiation of GMCs into myofibroblasts. In vivo, specific KO of Pdgfra inhibited GMC activation and vascular fibrosis, resulting in suppression of neointima formation and improvement of AVF patency despite CKD. Our findings could yield strategies for maintaining AVF functions.

Authors

Ke Song, Ying Qing, Qunying Guo, Eric K. Peden, Changyi Chen, William E. Mitch, Luan Truong, Jizhong Cheng

×

Figure 5

Internalization of PDGFRA in early endosome is required for TGFB1-induced GMC differentiation.

Options: View larger image (or click on image) Download as PowerPoint
Internalization of PDGFRA in early endosome is required for TGFB1-induce...
(A) Representative images of the location of PDGFRA in the endosome (EEA1-positive) after different treatment. PDGFRA was accumulated during CQ treatment and was colocalized with EEA1 at the perinuclear area. Scale bars: 10 μm. (B and C) Western blot (WB) and densitometric analysis showing the changes of proteasome inhibitor (MG132, 10 μM) on the TGFB1-induced responses in GMCs. Protein expression of PDGFRA was normalized to GAPDH and expressed as fold change of Ctl GMCs (C). (D and E) WB and densitometric analysis showing the changes of endosome inhibitor (NH4Cl, 20 mM and CQ, 50 μM) on the TGFB1-induced PDGFRA degradation and activation of downstream signals in GMCs. Protein expression of PDGFRA was normalized to GAPDH and expressed as fold change of Ctl GMCs (E). Data are presented as mean ± SEM (n = 4). One-way ANOVA was used for statistical analysis. **P < 0.01 versus Ctl; ##P < 0.01 versus corresponding TGFB1-treated group. GMC, GLI1-positive mesenchymal stem cell; EEA1, early endosome antigen 1; Ctl, control.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts